Brookfield Corp’s Cytek Biosciences CTKB Stock Holding History

Brookfield Corp’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-67,084	Closed	-$987K	–	615
2022 Q3	$987K	Buy	+67,084	New	+$871K	﹤0.01%	537

Other funds holding CTKB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Brookfield Corp's CTKB Position: Q4 2022 in Review

Brookfield Corp sold out of Cytek Biosciences (CTKB) in Q4 2022, closing a stake of 67,084 shares — an estimated $987K sold.

Brookfield Corp first reported a position in CTKB in Q3 2022 and held it in 1 quarter. The position peaked at $987K in Q3 2022. 103 funds tracked by Wall St. Rank hold CTKB as of Q4 2022.

Brookfield Corp reported no remaining Cytek Biosciences position as of Q4 2022 after selling out during the quarter.
Brookfield Corp sold 67,084 Cytek Biosciences shares in Q4 2022, an estimated $987K.
Brookfield Corp first reported a position in Cytek Biosciences in Q3 2022 and held it in 1 quarter.
Brookfield Corp's Cytek Biosciences position peaked at $987K in Q3 2022.
103 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2022.

Based on Brookfield Corp's 13F filing for Q4 2022, filed 14 Feb 2023.